Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 16, 2004

View Archived Issues

Stevioside found safe and effective in mild essential hypertension

Long-term budesonide found cost-effective in mild persistent asthma of early onset

New GABA-A modulators for anxiety, convulsions, cognitive disorders, etc.

Amgen patent covers COX-2 inhibitors and their use in inflammation and pain

Pharmacia scientists describe novel fluorinated LXR modulators

New PPARalpha agonists discovered by Kyorin researchers

Novel NK1 antagonists in early development at Kyorin

GSK scientists present new 5-HT receptor antagonists with antipsychotic activity

Novel VR1 antagonists with analgesic activity developed at Amgen

Seroquel receives FDA approval for bipolar-associated mania

Actilon enters phase I for chronic HCV

Pipeline progress report from Tularik

Salix launches Azasan

Initial dosing completed in phase I trial of MRE-0094

Nexium i.v. completes European MRP

Exelixis reviews development pipeline

Australian Cancer Technology expands pipeline with European and U.S. focus

Isis identifies SARS antisense drug candidates

Aastrom Biosciences evaluates Tissue Repair Cell product for tibial fractures

SB-715992 enters broad phase II program for cancer

Dosing commenced in phase II adult AML trial of clofarabine

Letrozole reduces the need for gonadotropins in infertile women undergoing IUI

Magnesium intake and risk of type 2 diabetes in healthy adult women

Improved control of CINV found after adding aprepitant to standard antiemetic regimen

NIP-222, a novel PPARgamma agonist for diabetic nephropathy

Small molecule CCR5 inhibitor tested against SIV

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 16, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 16, 2025.
Deals and an M&A strengthen end-of-year numbers
BioWorld
Two large deals and an acquisition, totaling about $4.64 billion in all, are helping wrap up what’s turning out to be a strong year. Through the first 11 months...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...
Radiopharm Theranostics’ RAD-101 meets brain metastases endpoints
BioWorld
Radiopharm Theranostics Ltd.’s radiotracer RAD-101 met the primary endpoint in 92% of patients in the phase IIb imaging trial in brain metastases, according to...